Sprog:
Valuta:
0 VARER - $0.00 Bonus: 2
Generic Glyxambi (Linagliptin/empagliflozin)
Glyxambi
Glyxambi is a prescription medication used to control blood sugar in adults with type 2 diabetes. It combines empagliflozin and linagliptin to help regulate glucose levels and support overall glycemic management.
Vælg Doser: 25/5mg
25/5mg
30piller
Glyxambi $194.39
$161.99
$5.40 pr pille
+ Forsikring på pakke levering
+ 10% rabat på fremtidige ordrer
Tilføj til kurv
spar: $0.00
25/5mg
60piller
Glyxambi $382.31
$318.59
$5.31 pr pille
+ Free trackable courier service
+ Forsikring på pakke levering
+ 10% rabat på fremtidige ordrer
Tilføj til kurv
spar: $5.40
25/5mg
90piller
Glyxambi $559.43
$466.19
$5.18 pr pille
+ Free trackable courier service
+ Forsikring på pakke levering
+ 10% rabat på fremtidige ordrer
Tilføj til kurv
spar: $19.80
Package Example
Din ordre vil blive pakket sikkert og trygt og sendes afsendt inden for 24 timer. Dette er præcist, hvordan din pakke vil se ud (billederne af et ægte fragt vare). Det har en størrelse og et udseende af et almindeligt brev (9.4x4.3x0.3 inches eller 24x11x0.7cm), og det afslører ikke indholdet
Leveringstiden
Levering 14-21 dage 10$ Sporing # tilgængelig i 4 dage
Gratis standard luftfragt for alle ordrer med et beløb over $200
Levering 5-9 dage 30$ Sporing # tilgængelig i 2 dage
Gratis sporbar service for alle ordrer med et beløb over $300
Forsendelse til hele verden Fortrolighed og anonymitet er garanteret
Trygt og sikkert Discreet looking packages
Forsendelse af ordrer inden for 24 timer 100% levering success
Vidnesbyrder Vare Beskrivelse
Der er i øjeblikket ingen anmeldelse af dette produkt, men du kan være den første eller du kan læse mere om relaterede produkter på siden med kundeudtalelser.

Tilføj Bedømmelse

Common Use
Glyxambi is prescribed for adults with type 2 diabetes whose blood sugar is not adequately controlled by diet and exercise alone. It helps lower blood glucose by promoting glucose excretion through urine and enhancing the body’s natural insulin response. Maintaining proper blood sugar levels reduces the risk of diabetes-related complications.

Dosage and Direction
The recommended dose is one tablet taken orally once daily, with or without food, or as directed by a healthcare provider. Swallow the tablet whole with water and take it at the same time each day. Do not change the dose without consulting your doctor.

Precautions
Before using Glyxambi, inform your doctor if you have kidney or liver disease, low blood pressure, or a history of urinary tract infections. Monitor blood sugar regularly and stay hydrated to avoid dehydration. Avoid driving or operating machinery if you experience dizziness or low blood sugar.

Contraindications
Glyxambi should not be used in patients with type 1 diabetes, diabetic ketoacidosis, severe kidney impairment, or known hypersensitivity to empagliflozin, linagliptin, or any component of the tablet.

Possible Side Effects
Common side effects include urinary tract infections, hypoglycemia (especially when combined with insulin), headache, and nasopharyngitis. Rare but serious effects may include dehydration, kidney problems, or ketoacidosis. Seek medical attention if severe symptoms occur.

Drug Interaction
Glyxambi may interact with insulin, sulfonylureas, diuretics, or other medications affecting kidney function or blood sugar. These interactions can increase the risk of hypoglycemia or dehydration. Inform your healthcare provider about all medications and supplements you are taking.

Missed Dose
If a dose is missed, take it as soon as you remember. If it is close to the time of the next dose, skip the missed dose. Do not take a double dose to make up for a missed one.

Overdose
Overdose may cause severe hypoglycemia, dehydration, or kidney problems. Seek immediate medical attention if an overdose is suspected.

Storage
Store Glyxambi tablets at room temperature, away from heat, moisture, and direct sunlight. Keep out of reach of children. Do not use after the expiration date.

Disclaimer

We provide only general information about medications which does not cover all directions, possible drug integrations, or precautions. Information at the site cannot be used for self-treatment and self-diagnosis. Any specific instructions for a particular patient should be agreed with your health care adviser or doctor in charge of the case. We disclaim reliability of this information and mistakes it could contain. We are not responsible for any direct, indirect, special or other indirect damage as a result of any use of the information on this site and also for consequences of self-treatment.

Vidnesbyrder
Edmond fra UK
Hvis der ikke var online salg af generiske lægemidler, ville jeg have spilt mange penge på dyre lægemidler. Kvalitetten er god, og det fungerer på den måde som beskrevet. Jeg vil gerne takke dem, der startede det. Jeg bestiller snart min fjerde potion ...
Farya Pirbazari, West Vancouver, Canada
Jeg modtog både mine gensendte tabletter (30 x 20 mg Cialis) sammen med min nye bestilling (20 x 50 mg Viagra) i dag. Mange tak for jeres ærlighed. Fra nu af vil jeg ikke blot være en permanent kunde, men jeg vil helt sikkert også anbefale jer til venner, ...
Isabella fra Rom
Jeg vil gerne anbefale Ayurslim til alle. Jeg har kæmpet med min ”ekstra vægt” i flere år. Jeg har prøvet forskellige talje trimmere og bælter, men med disse piller, begyndte jeg at spise mindre. Jeg føler næsten ikke sult længere og jeg tabte mig på ...
Læs mere...

Leveringsmetoder

Sikker Betalingsmetode
Nyheder
First drug to delay onset of type 1 diabetes made available on NHS
The immunotherpay can give children and adults three extra years before they need to use insulin.
Puberty blocker trial will help reduce harm, says Cass report author
Dr Hilary Cass says she is "absolutely convinced that more children will be harmed if we don't do the trial than if we do."
Jeremy Clarkson in remission from prostate cancer
The presenter shared his "aggressive" cancer diagnosis on an episode of Clarkson's Farm earlier this week.
Minimum age of 11 set for UK puberty blocker trial
Gender-questioning children will have to be at least 11 years old to take part in a clinical trial of puberty-blocking drugs.